We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 564683

CAS#: 183293-82-5

Description: Gemcabene is a lipid altering agent which lowers low-density lipoprotein cholesterol (LDL-C) and decreases triglycerides. Gemcabene increases high density lipoprotein (HDL) cholesterol levels and HDL particle size.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-07-14. Prices are subject to change without notice.

Gemcabene is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 564683
Name: Gemcabene
CAS#: 183293-82-5
Chemical Formula: C16H30O5
Exact Mass: 302.2093
Molecular Weight: 302.41
Elemental Analysis: C, 63.55; H, 10.00; O, 26.45

Synonym: PD72953; PD 72953; PD-72953; Gemcabene

IUPAC/Chemical Name: 6,6'-Oxybis(2,2-dimethylhexanoic acid)


InChi Code: InChI=1S/C16H30O5/c1-15(2,13(17)18)9-5-7-11-21-12-8-6-10-16(3,4)14(19)20/h5-12H2,1-4H3,(H,17,18)(H,19,20)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Srivastava RAK, Cornicelli JA, Markham B, Bisgaier CL. Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain. Front Pharmacol. 2018 May 11;9:471. doi: 10.3389/fphar.2018.00471. eCollection 2018. PubMed PMID: 29867478; PubMed Central PMCID: PMC5958179.

2: Oniciu DC, Hashiguchi T, Shibazaki Y, Bisgaier CL. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. PLoS One. 2018 May 30;13(5):e0194568. doi: 10.1371/journal.pone.0194568. eCollection 2018. PubMed PMID: 29847555; PubMed Central PMCID: PMC5976190.

3: Srivastava RAK, Cornicelli JA, Markham B, Bisgaier CL. Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism. Mol Cell Biochem. 2018 Dec;449(1-2):167-183. doi: 10.1007/s11010-018-3353-5. Epub 2018 Apr 11. PubMed PMID: 29644527; PubMed Central PMCID: PMC6223808.

4: Bisgaier CL, Oniciu DC, Srivastava RAK. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease. J Cardiovasc Pharmacol. 2018 Jul;72(1):3-10. doi: 10.1097/FJC.0000000000000580. PubMed PMID: 29621036; PubMed Central PMCID: PMC6039382.